{"id":"vonoprazan-amoxicillin-clarithromycin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Taste disturbance"},{"rate":"3-8","effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"0cb2ee04-8581-46c8-a781-7be170ab5c86","title":"VOQUEZNA DUAL PAK (VONOPRAZAN FUMARATE AND AMOXICILLIN) KIT VOQUEZNA TRIPLE PAK (VONOPRAZAN FUMARATE, AMOXICILLIN AND CLARITHROMYCIN) KIT [PHATHOM PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vonoprazan is a potassium-competitive acid blocker that inhibits the proton pump to reduce gastric acid secretion, creating an environment where amoxicillin and clarithromycin can effectively penetrate and kill H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis, while clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. Together, these three agents form a standard triple-therapy regimen for H. pylori eradication.","oneSentence":"This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:54.562Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"},{"name":"Peptic ulcer disease associated with H. pylori"}]},"trialDetails":[{"nctId":"NCT07179159","phase":"NA","title":"Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yanqing Li","startDate":"2025-09-09","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":372},{"nctId":"NCT07224035","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-15","conditions":"H Pylori Infection, H Pylori Gastritis, Gastric Cancer","enrollment":500},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":"HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":66},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":"Helicobacter Pylori Eradication","enrollment":390},{"nctId":"NCT07275827","phase":"PHASE3","title":"Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":88},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","enrollment":400},{"nctId":"NCT06514274","phase":"PHASE4","title":"Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-09-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":558},{"nctId":"NCT07040839","phase":"PHASE4","title":"Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-07","conditions":"H Pylori","enrollment":128},{"nctId":"NCT06959368","phase":"PHASE4","title":"Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication","status":"RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-03-25","conditions":"Helicobacter Pylori Infection","enrollment":484},{"nctId":"NCT06576882","phase":"PHASE3","title":"7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-30","conditions":"Helicobacter Pylori Infection, Gastritis, Vonoprazan","enrollment":326},{"nctId":"NCT05957432","phase":"PHASE2","title":"Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-08-15","conditions":"Helicobacter Pylori Infection","enrollment":90},{"nctId":"NCT06162949","phase":"PHASE3","title":"Vonoprazan for Helicobacter Pylori Eradication in Adolescents","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":"Treatment Effectiveness","enrollment":242},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT06250634","phase":"NA","title":"Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-02-10","conditions":"Helicobacter Pylori Infection","enrollment":806},{"nctId":"NCT06414707","phase":"PHASE3","title":"Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-12","conditions":"Helicobacter Pylori Infection","enrollment":320},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"Helicobacter Pylori Eradication","enrollment":232},{"nctId":"NCT06037122","phase":"","title":"Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09","conditions":"Helicobacter Pylori Infection","enrollment":558},{"nctId":"NCT04198363","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-04-30","conditions":"Helicobacter Pylori","enrollment":510},{"nctId":"NCT04753437","phase":"PHASE1","title":"A Study of Vonoprazan in Adults With Helicobacter Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-06","conditions":"Helicobacter Pylori","enrollment":44},{"nctId":"NCT06004401","phase":"NA","title":"The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-20","conditions":"The Eradication Rate of Helicobacter Pylori","enrollment":400},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT05049902","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-09-21","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT05419674","phase":"PHASE4","title":"Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection","enrollment":393},{"nctId":"NCT04850209","phase":"NA","title":"The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-07-23","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication, Patient Education","enrollment":438},{"nctId":"NCT05014334","phase":"PHASE4","title":"Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2021-12-01","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":300},{"nctId":"NCT05590286","phase":"PHASE4","title":"A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2022-06-01","conditions":"Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor","enrollment":100},{"nctId":"NCT05345210","phase":"PHASE4","title":"Vonoprazan Hp Dual or Triple Eradication Regimes","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-04-25","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":"Helicobacter Pylori Infection","enrollment":1046},{"nctId":"NCT05301725","phase":"","title":"Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy Against Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori; Eradication Rate","enrollment":670},{"nctId":"NCT05189444","phase":"NA","title":"The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-03-25","conditions":"Helicobacter Pylori Infection","enrollment":672},{"nctId":"NCT05196945","phase":"PHASE4","title":"Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication of Helicobacter Pylori -- a Multicenter, Randomized, Parallel Controlled Study","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-03-31","conditions":"Helicobacter Pylori Eradication Rate","enrollment":316},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04901663","phase":"PHASE4","title":"Vonoprazan in Helicobacter Pylori Treatment an RCT","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2021-06-21","conditions":"Helicobacter Pylori Infection","enrollment":179},{"nctId":"NCT04991584","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-08-04","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT03050307","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-17","conditions":"Gastric Ulcer","enrollment":234},{"nctId":"NCT04901117","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-06","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT03908619","phase":"PHASE4","title":"A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2019-04-16","conditions":"Helicobacter Pylori Infection","enrollment":252},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533},{"nctId":"NCT02827942","phase":"PHASE3","title":"Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication","status":"COMPLETED","sponsor":"Hamamatsu University","startDate":"2016-07-01","conditions":"Gastritis Associated With Helicobacter Pylori","enrollment":112},{"nctId":"NCT03219723","phase":"","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-09-01","conditions":"Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other","enrollment":560},{"nctId":"NCT02761005","phase":"PHASE2","title":"Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori","status":"UNKNOWN","sponsor":"Hamamatsu University","startDate":"2016-05","conditions":"H. Pylori Infection","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vonoprazan + amoxicillin + clarithromycin","genericName":"Vonoprazan + amoxicillin + clarithromycin","companyName":"The Third Xiangya Hospital of Central South University","companyId":"the-third-xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin). Used for Helicobacter pylori infection eradication, Peptic ulcer disease associated with H. pylori.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}